MedTrace Logo

Stellate Ganglion Block in Herpes Zoster

NCT04188327 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2025-02-13

No results posted yet for this study

Summary

Patient who will be presented to Tanta University Hospitals complaining of acute herpes zoster with onset of vesicular eruption less than 7 days will be included in this clinical study.

Patients will be excluded if they refused participation, had allergy to local anesthetics, coagulopathy, local infection, glaucoma, or neurological deficit.

All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the patients will be classified into two groups:- Group I (control group): Patients will receive sham block weekly for three times Group III (SGB group): Patients will receive stellate ganglion block weekly for three times

The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of complication will be measured.

Conditions

Interventions

PROCEDURE

Stellate ganglion block

While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg). Each patient will receive: * Acyclovir 800 mg orally every 5 times per day 7 days. * Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours

PROCEDURE

Sham Stellate ganglion block

The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle. Each patient will receive: * Acyclovir 800 mg orally every 5 times per day for 7 days. * Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours

Sponsors & Collaborators

  • Mohamad Gamal Elmawy, M.D

    collaborator UNKNOWN

  • Tanta University

    lead OTHER

Principal Investigators

  • Sameh Ismaiel, M.D · Lecturer of Anesthesia and Intensive Care, Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2025-02-02
Completion
2025-02-02

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04188327 on ClinicalTrials.gov